Nintedanib Adalvo

Nintedanib, the active ingredient in Nintedanib Adalvo, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease in adult patients.

GNH USA supplies Nintedanib Adalvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and pharmacies worldwide.

Nintedanib is an antifibrotic agent used in fibrotic lung disease management.

- Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and delays worsening of respiratory symptoms.

Nintedanib may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often manageable with hydration. - Abdominal pain: cramp‑like discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Vomiting: occasional expulsion of stomach contents. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Hepatic injury: potential for serious liver damage. - Bleeding events: increased risk of gastrointestinal or other hemorrhage. - Cardiovascular events: rare cases of myocardial infarction or stroke. - Severe infections: opportunistic infections in immunocompromised patients. - Gastrointestinal perforation: rare but life‑threatening. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: perform baseline liver tests and repeat periodically. - Bleeding risk: avoid concomitant use of strong anticoagulants unless medically necessary. - Pregnancy: safety unknown; avoid use during pregnancy and discuss contraception. - Drug interactions: review all concomitant medications for potential interactions. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nintedanib may interact with several drug classes; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Antiplatelet agents (e.g., clopidogrel): increased hemorrhagic potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - P‑gp inhibitors (e.g., verapamil): may raise plasma levels. - Diuretics: monitor electrolytes and renal function.